LGM Pharma has announced the second phase of its Contract Development and Manufacturing Organisation (CDMO) growth strategy, committing an additional USD 9 million to its facilities in Rosenberg, Texas and Colorado Springs, Colorado. The investment follows the company’s previously announced USD 6 million expansion in Rosenberg in 2025, and is designed to increase commercial capacity, expand R&D capabilities and support continued demand for the US-based drug product manufacturing.

The Texas facility enhancements include a USD 4 million investment to expand commercial-scale manufacturing suites for suppositories in response to increasing customer and market demand, including growth in women’s health products. The upgrades also expand R&D capabilities to support formulation and scale-up for suppositories, solutions, suspensions and semi-solids. The Rosenberg site will remain fully operational throughout construction, with upgrades already underway.

In Colorado Springs, LGM Pharma will invest USD 5 million to expand commercial manufacturing capacity for niche, high-value Oral Solid Dose (OSD) products, including Orally Disintegrating Tablets (ODTs). The facility has served as the company’s Centre of Excellence (CoE) for OSD development. The expansion, planned for completion this year, will support growing demand for domestic manufacturing. In 2024, the global OSD CDMO market was valued at USD 43.65 billion, with North America accounting for approximately 40.5 percent of global OSD pharmaceutical manufacturing activity.

“These multi-site investments totaling USD 15 million reflect our continued commitment to strengthening pharmaceutical supply chains in the United States. Today’s pharma companies need partners that are both resilient and integrated across the full product lifecycle. By reinforcing domestic drug product manufacturing at the downstream end of the supply chain, closer to end markets, and leveraging our global API sourcing capabilities upstream, we create a balanced end-to-end model. This gives customers greater control and visibility as they move products from development to commercialisation,” said Prasad Raje, Chief Executive Officer, LGM Pharma.

Earlier in the supply chain, at the drug substance stage, LGM Pharma supports 505(b)(2), NDA and ANDA programmes through a global network of more than 220 pre-qualified Active Pharmaceutical Ingredients (API) manufacturers. By combining global drug substance sourcing with expanded US finished dose development and manufacturing, the company provides integrated support across the full drug product lifecycle.

Hamilton Lenox, Chief Commercial Officer, LGM Pharma, said the company’s prior Rosenberg upgrades from phase-I of the expansion, including implementation of enhanced track-and-trace serialisation systems and increased production volumes, are now complete.

“We are executing this next phase of expansion while keeping both facilities fully operational. Our teams are experienced in managing complex upgrades without sacrificing quality or disrupting customer supply, which remain our top operational priorities. Rather than overextending in a single phase, we are executing these enhancements incrementally to expand capabilities and capacity while ensuring operational continuity. This approach allows us to strengthen infrastructure, support customer growth and scale in response to market demand.”